Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPID | Q08752 | 3/20 | 0.39 |
| ▸ | PPIB | P23284 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | PPIG | Q13427 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638678 | 0.87 | L3MBTL1 (0.43) | DRD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL1638619 | 0.84 | L3MBTL1 (0.40) | DRD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL1206601 | 0.84 | NAMPT (0.43) | DRD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL1636536 | 0.83 | DRD2 (0.40) | DRD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL1637283 | 0.82 | DRD2 (0.40) | DRD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL1638611 | 0.81 | CA1 (0.43) | DRD2L3MBTL1CA1CA2CTSK | |
| SCHEMBL1638182 | 0.80 | PPARA (0.35) | DRD2 | |
| SCHEMBL1206266 | 0.80 | CXCR4 (0.48) | DRD2L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL1637610 | 0.80 | NAMPT (0.46) | L3MBTL1NAMPTCA1CA2AKT1 | |
| SCHEMBL1638691 | 0.79 | TDP1 (0.48) | DRD2CA1CA2CTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | DRD2 175/4885L3MBTL1 884/4885PPID 4349/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | DRD2 257/4885L3MBTL1 1179/4885PPID 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.